; and (ii) drugs approved as a breakthrough therapy pursuant to section 506(a), as a fast track product pursuant to section 506(b), or pursuant to accelerated approval under section 506(c); and (B) exclude any drug (including any biological product) that is a selected drug (as referred to in section 1192(c) of the Social Security Act), with respect to a price applicability period (as defined in section 1191(b)(2) of such Act). (c) Publication The Secretary shall publish each independent value assessment prepared under subsection (a) or (b) on the public website of the Department of Health and Human Services without modification, except that the Secretary may redact any confidential or proprietary information in accordance with applicable law. (d) Contracts (1) In general To the extent and in the amounts made available in advance in appropriations Acts, the Secretary shall enter into a contract with an eligible entity to develop independent value assessments under this section. (2) Eligible entities To be eligible to prepare an independent value assessment under this section, an entity— (A) shall be a nonprofit organization, a university, a federally funded research and development center, or another type of organization that is determined by the Secretary to be capable of developing such an independent value assessment; (B) shall not be an entity that— (i) is involved in the manufacturing, research, and development of drugs; or (ii) operates fully insured or self-insured health plans, pharmaceutical benefit managers, or other entities that pay for drugs